Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 2—February 2008


Cost-effectiveness of Human Papillomavirus Vaccination in the United States

Harrell W. Chesson*Comments to Author , Donatus U. Ekwueme*, Mona Saraiya*, and Lauri E. Markowitz*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Table 1

Estimated cost per QALY gained by adding routine HPV vaccination of 12-y-old girls to existing cervical cancer screening in the United States*

Parameter Population model
Cohort model;
no herd immunity, $US
No herd immunity, $US Herd immunity, $US
Excluding anal, vaginal, vulvar, and oropharyngeal cancers
Vaccine targets HPV types 6,11,16,18 10,294 5,336 8,593
Vaccine targets HPV types 16,18
Including anal, vaginal, vulvar, and orophayngeal cancers†
Vaccine targets HPV types 6,11,16,18 8,137 3,906 6,430
Vaccine targets HPV types 16,18 11,602 7,848 9,471

*When applying base-case parameter values to 12 model variations. QALY, quality-adjusted life year; HPV, human papillomavirus.
†The oropharyngeal cancer sites we included were base of tongue, tonsillar, and other sites as described in the Technical Appendix.

Main Article